Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers [1][3] - The company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [2] Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA, found in 14% to 17% of cancer patients [3] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, an oral selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral selective inhibitor of ribonucleotide reductase (RNR) [3] - These candidates are currently being evaluated in the phase 1/2 POTENTIATE clinical trial for patients with oncogene amplified cancers [3] - Additionally, Boundless Bio is conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable selective Kinesin degrader [3] - The company is headquartered in San Diego, CA [3]